{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:47:18Z","timestamp":1785527238344,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11060-026-05699-w","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:49:08Z","timestamp":1783442948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and predictors of hemorrhage in pediatric low-grade glioma"],"prefix":"10.1007","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0369-9704","authenticated-orcid":false,"given":"Eric A.","family":"Grin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7582-8670","authenticated-orcid":false,"given":"Spencer","family":"Frome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Clymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3237-6037","authenticated-orcid":false,"given":"Yosef","family":"Dastagirzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-6595","authenticated-orcid":false,"given":"David H.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0053-8658","authenticated-orcid":false,"given":"Eveline Teresa","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-1286","authenticated-orcid":false,"given":"Devorah","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"5699_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaoncol.2024.5506","volume":"11","author":"C Horbinski","year":"2025","unstructured":"Horbinski C, Solomon DA, Lukas RV, Packer RJ, Brastianos P, Wen PY et al (2025) Molecular testing for the world health organization classification of central nervous system tumors: A review. JAMA Oncol 11:317\u2013328","journal-title":"JAMA Oncol"},{"key":"5699_CR2","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1056\/NEJMra2116344","volume":"386","author":"AR Cohen","year":"2022","unstructured":"Cohen AR (2022) Brain tumors in children. N Engl J Med 386:1922\u20131931","journal-title":"N Engl J Med"},{"key":"5699_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1470-2045(25)00297-9","volume":"26","author":"R Hoogendijk","year":"2025","unstructured":"Hoogendijk R, Capocaccia R, van der Lugt J, Kranendonk MEG, Hoving EW, Wesseling P et al (2025) Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 european countries (eurocare-6): A population-based study. Lancet Oncol 26:1091\u20131099","journal-title":"Lancet Oncol"},{"key":"5699_CR4","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro J, Witt O, Hernaiz Driever P, Bag AK, de Blank P, Kadom N et al (2020) Response assessment in paediatric low-grade glioma: Recommendations from the response assessment in pediatric neuro-oncology (rapno) working group. Lancet Oncol 21:e305\u2013e316","journal-title":"Lancet Oncol"},{"key":"5699_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11910-023-01257-3","volume":"23","author":"SF Sait","year":"2023","unstructured":"Sait SF, Giantini-Larsen AM, Tringale KR, Souweidane MM, Karajannis MA (2023) Treatment of pediatric low-grade gliomas. Curr Neurol Neurosci Rep 23:185\u2013199","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5699_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-025-01238-9","volume":"40","author":"KB Peters","year":"2026","unstructured":"Peters KB (2026) New and emerging therapies for patients with low-grade glioma. CNS Drugs 40:1\u201318","journal-title":"CNS Drugs"},{"key":"5699_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garre ML, Hara J, Plant-Fox A, Aerts I et al (2023) Dabrafenib plus trametinib in pediatric glioma with braf v600 mutations. N Engl J Med 389:1108\u20131120","journal-title":"N Engl J Med"},{"key":"5699_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3171\/JNS\/2008\/108\/2\/0223","volume":"108","author":"JB White","year":"2008","unstructured":"White JB, Piepgras DG, Scheithauer BW, Parisi JE (2008) Rate of spontaneous hemorrhage in histologically proven cases of pilocytic astrocytoma. J Neurosurg 108:223\u2013226","journal-title":"J Neurosurg"},{"key":"5699_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3171\/2019.12.JNS192155","volume":"134","author":"Y Ishi","year":"2021","unstructured":"Ishi Y, Yamaguchi S, Hatanaka KC, Okamoto M, Motegi H, Kobayashi H et al (2021) Association of the fgfr1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients. J Neurosurg 134:733\u2013741","journal-title":"J Neurosurg"},{"key":"5699_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10143-018-0969-6","volume":"43","author":"CA Donofrio","year":"2020","unstructured":"Donofrio CA, Gagliardi F, Callea M, da Passano CF, Terreni MR, Cavalli A et al (2020) Pediatric cerebellar pilocytic astrocytoma presenting with spontaneous intratumoral hemorrhage. Neurosurg Rev 43:9\u201316","journal-title":"Neurosurg Rev"},{"key":"5699_CR11","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/j.ijrobp.2011.01.019","volume":"81","author":"KS Oh","year":"2011","unstructured":"Oh KS, Hung J, Robertson PL, Garton HJ, Muraszko KM, Sandler HM et al (2011) Outcomes of multidisciplinary management in pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 81:e481\u2013488","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5699_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00401-021-02276-5","volume":"141","author":"MJ Fisher","year":"2021","unstructured":"Fisher MJ, Jones DTW, Li Y, Guo X, Sonawane PS, Waanders AJ et al (2021) Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (nf1). Acta Neuropathol 141:605\u2013617","journal-title":"Acta Neuropathol"},{"key":"5699_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41379-020-00659-9","volume":"34","author":"K Giannikou","year":"2021","unstructured":"Giannikou K, Zhu Z, Kim J, Winden KD, Tyburczy ME, Marron D et al (2021) Subependymal giant cell astrocytomas are characterized by mtorc1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Mod Pathol 34:264\u2013279","journal-title":"Mod Pathol"},{"key":"5699_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1365-2990.2010.01113.x","volume":"36","author":"M Sie","year":"2010","unstructured":"Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF (2010) Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol Appl Neurobiol 36:636\u2013647","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5699_CR15","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1073\/pnas.1219232110","volume":"110","author":"AJ Sievert","year":"2013","unstructured":"Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N et al (2013) Paradoxical activation and raf inhibitor resistance of braf protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 110:5957\u20135962","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5699_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1749-6632.2000.tb06313.x","volume":"902","author":"G Pages","year":"2000","unstructured":"Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F et al (2000) Signaling angiogenesis via p42\/p44 map kinase cascade. Ann N Y Acad Sci 902:187\u2013200","journal-title":"Ann N Y Acad Sci"},{"key":"5699_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1023\/A:1026506011458","volume":"19","author":"E Berra","year":"2000","unstructured":"Berra E, Pages G, Pouyssegur J (2000) Map kinases and hypoxia in the control of vegf expression. Cancer Metastasis Rev 19:139\u2013145","journal-title":"Cancer Metastasis Rev"},{"key":"5699_CR18","doi-asserted-by":"publisher","first-page":"e0220146","DOI":"10.1371\/journal.pone.0220146","volume":"14","author":"S Yamashita","year":"2019","unstructured":"Yamashita S, Takeshima H, Matsumoto F, Yamasaki K, Fukushima T, Sakoda H et al (2019) Detection of the kiaa1549-braf fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma. PLoS ONE 14:e0220146","journal-title":"PLoS ONE"},{"key":"5699_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3171\/2015.10.PEDS1580","volume":"17","author":"MP Wilson","year":"2016","unstructured":"Wilson MP, Johnson ES, Hawkins C, Atkins K, Alshaya W, Pugh JA (2016) Hemorrhagic presentations of cerebellar pilocytic astrocytomas in children resulting in death: Report of 2 cases. J Neurosurg Pediatr 17:446\u2013452","journal-title":"J Neurosurg Pediatr"},{"key":"5699_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.wneu.2018.12.032","volume":"123","author":"A Pagano","year":"2019","unstructured":"Pagano A, Novegno F, Ferlosio A, Lunardi P (2019) Repeat bleeding 18 years after hemorrhagic pilocytic astrocytoma: Prognostic implications of conservative management-case report and literature review. World Neurosurg 123:328\u2013338","journal-title":"World Neurosurg"},{"key":"5699_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00401-018-1874-3","volume":"136","author":"RR Yang","year":"2018","unstructured":"Yang RR, Aibaidula A, Wang WW, Chan AK, Shi ZF, Zhang ZY et al (2018) Pediatric low-grade gliomas can be molecularly stratified for risk. Acta Neuropathol 136:641\u2013655","journal-title":"Acta Neuropathol"},{"key":"5699_CR22","doi-asserted-by":"publisher","first-page":"e70023","DOI":"10.1111\/bpa.70023","volume":"35","author":"S Zahedi","year":"2025","unstructured":"Zahedi S, Riemondy K, Liu T, Griesinger AM, Donson AM, Apfelbaum AA et al (2025) Multi-pronged analysis of pediatric low-grade glioma and ganglioglioma reveals a unique tumor microenvironment associated with braf alterations. Brain Pathol 35:e70023","journal-title":"Brain Pathol"},{"key":"5699_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ccr.2005.12.021","volume":"9","author":"G Mavria","year":"2006","unstructured":"Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R et al (2006) Erk-mapk signaling opposes rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9:33\u201344","journal-title":"Cancer Cell"},{"key":"5699_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-24-3439","volume":"31","author":"S Singh","year":"2025","unstructured":"Singh S, Bradford D, Chatterjee S, Li X, Aungst SL, Skinner AM et al (2025) Fda approval summary: Tovorafenib for relapsed or refractory braf-altered pediatric low-grade glioma. Clin Cancer Res 31:1383\u20131389","journal-title":"Clin Cancer Res"},{"key":"5699_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12885-024-11820-x","volume":"24","author":"CM van Tilburg","year":"2024","unstructured":"van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA, Cruz-Martinez O et al (2024) Loggic\/firefly-2: A phase 3, randomized trial of tovorafenib vs. Chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating raf alteration. BMC Cancer 24:147","journal-title":"BMC Cancer"},{"key":"5699_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES et al (2024) The type ii raf inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: The phase 2 firefly-1 trial. Nat Med 30:207\u2013217","journal-title":"Nat Med"},{"key":"5699_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3171\/2014.8.PEDS14146","volume":"15","author":"MA El-Gaidi","year":"2015","unstructured":"El-Gaidi MA, El-Nasr AH, Eissa EM (2015) Infratentorial complications following preresection csf diversion in children with posterior fossa tumors. J Neurosurg Pediatr 15:4\u201311","journal-title":"J Neurosurg Pediatr"},{"key":"5699_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1227\/neu.0000000000002908","volume":"95","author":"KW Chen","year":"2024","unstructured":"Chen KW, Chen YR, Yang LY, Cheng YW, Chou SC, Chen YH et al (2024) Microcirculatory impairment and cerebral injury in hydrocephalus and the effects of cerebrospinal fluid diversion. Neurosurgery 95:469\u2013479","journal-title":"Neurosurgery"},{"key":"5699_CR29","doi-asserted-by":"publisher","first-page":"e0158506","DOI":"10.1371\/journal.pone.0158506","volume":"11","author":"C Haubrich","year":"2016","unstructured":"Haubrich C, Czosnyka M, Diehl R, Smielewski P, Czosnyka Z (2016) Ventricular volume load reveals the mechanoelastic impact of communicating hydrocephalus on dynamic cerebral autoregulation. PLoS ONE 11:e0158506","journal-title":"PLoS ONE"},{"key":"5699_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jocn.2008.02.016","volume":"16","author":"R Santhanam","year":"2009","unstructured":"Santhanam R, Balasubramaniam A, Chandramouli BA (2009) Fatal intratumoral hemorrhage in posterior fossa tumors following ventriculoperitoneal shunt. J Clin Neurosci 16:135\u2013137","journal-title":"J Clin Neurosci"},{"key":"5699_CR31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00401-022-02478-5","volume":"144","author":"CG Lucas","year":"2022","unstructured":"Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN et al (2022) Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol 144:747\u2013765","journal-title":"Acta Neuropathol"},{"key":"5699_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","volume":"104","author":"J Helfferich","year":"2016","unstructured":"Helfferich J, Nijmeijer R, Brouwer OF, Boon M, Fock A, Hoving EW et al (2016) Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol 104:30\u201341","journal-title":"Crit Rev Oncol Hematol"},{"key":"5699_CR33","doi-asserted-by":"publisher","first-page":"8588","DOI":"10.1158\/0008-5472.CAN-06-2220","volume":"67","author":"NM Warrington","year":"2007","unstructured":"Warrington NM, Woerner BM, Daginakatte GC, Dasgupta B, Perry A, Gutmann DH et al (2007) Spatiotemporal differences in cxcl12 expression and cyclic amp underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 67:8588\u20138595","journal-title":"Cancer Res"},{"key":"5699_CR34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ajpath.2010.11.031","volume":"178","author":"WE Parker","year":"2011","unstructured":"Parker WE, Orlova KA, Heuer GG, Baybis M, Aronica E, Frost M et al (2011) Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. Am J Pathol 178:296\u2013305","journal-title":"Am J Pathol"},{"key":"5699_CR35","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/onc.2014.164","volume":"34","author":"KM Dodd","year":"2015","unstructured":"Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR (2015) Mtorc1 drives hif-1alpha and vegf-a signalling via multiple mechanisms involving 4e-bp1, s6k1 and stat3. Oncogene 34:2239\u20132250","journal-title":"Oncogene"},{"key":"5699_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","volume":"4","author":"JB Brugarolas","year":"2003","unstructured":"Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG (2003) Jr. Tsc2 regulates vegf through mtor-dependent and -independent pathways. Cancer Cell 4:147\u2013158","journal-title":"Cancer Cell"},{"key":"5699_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/neuonc\/noz230","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold A, Yuan M, Price A, Harris L, Eberhart CG, Raabe EH (2020) Synergistic activity of mtorc1\/2 kinase and mek inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity. Neuro Oncol 22:563\u2013574","journal-title":"Neuro Oncol"},{"key":"5699_CR38","first-page":"2342","volume":"9","author":"N Chandrasekar","year":"2003","unstructured":"Chandrasekar N, Mohanam S, Lakka SS, Dinh DH, Olivero WC, Gujrati M et al (2003) Glial cell-induced endothelial morphogenesis is inhibited by interfering with extracellular signal-regulated kinase signaling. Clin Cancer Res 9:2342\u20132349","journal-title":"Clin Cancer Res"},{"key":"5699_CR39","doi-asserted-by":"publisher","first-page":"e0135245","DOI":"10.1371\/journal.pone.0135245","volume":"10","author":"MA Farhan","year":"2015","unstructured":"Farhan MA, Carmine-Simmen K, Lewis JD, Moore RB, Murray AG (2015) Endothelial cell mtor complex-2 regulates sprouting angiogenesis. PLoS ONE 10:e0135245","journal-title":"PLoS ONE"},{"key":"5699_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125\u2013132","journal-title":"Lancet"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05699-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:10:25Z","timestamp":1785521425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05699-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5699"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05699-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the NYU Langone Health Institutional Review Board. Patients\u2019 informed consent was obtained for all interventions, and the authors confirm that all research was conducted ethically in accordance with the principles outlined in the World Medical Association Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Devorah Segal has sat on scientific advisory boards for DayOne Biopharmaceuticals, Alexion, and Springworks. All other authors report no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}